Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial.
Saved in:
| Title: | Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial. |
|---|---|
| Authors: | Mell, Loren K1 (AUTHOR), Torres-Saavedra, Pedro A2 (AUTHOR), Wong, Stuart J3 (AUTHOR), Kish, Julie A4 (AUTHOR), Chang, Steven S5 (AUTHOR), Jordan, Richard C6 (AUTHOR), Liu, Tian7 (AUTHOR), Truong, Minh Tam8 (AUTHOR), Winquist, Eric W9 (AUTHOR), Takiar, Vinita10 (AUTHOR), Wise-Draper, Trisha11 (AUTHOR), Robbins, Jared R12 (AUTHOR), Rodriguez, Cristina P13 (AUTHOR), Awan, Musaddiq J14 (AUTHOR), Beadle, Beth M15 (AUTHOR), Henson, Christina16 (AUTHOR), Narayan, Samir17 (AUTHOR), Spencer, Sharon A18 (AUTHOR), Powell, Steven19 (AUTHOR), Dunlap, Neal20 (AUTHOR) |
| Source: | Lancet Oncology. Dec2024, Vol. 25 Issue 12, p1576-1588. 13p. |
| Database: | Academic Search Ultimate |
| ISSN: | 14702045 |
|---|---|
| DOI: | 10.1016/S1470-2045(24)00507-2 |
